AbbVie’s tavapadon holds potential to become prominent treatment in dopamine agonist market:… EP News Bureau Dec 20, 2024 Tavapadon’s profile and efficacy could redefine its role in Parkinson’s treatment, but market positioning remains a challenge,…
GE Healthcare announces first patient dosed in phase-III clinical trial for new dopamine transporter… EP News Bureau Mar 31, 2022 Next-stage clinical study also proceeding for SPECT radiopharma
